TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > At Last Digital Transformation is Embraced by the Healthcare Industry

At Last Digital Transformation is Embraced by the Healthcare Industry

At Last Digital Transformation is Embraced by the Healthcare Industry

Author: Susan Maue, Managing Director, PharmaLex US

The future of healthcare that we envision in 2040 will be a world apart from the current status quo. Emerging technology has become an integral part of our everyday personal and work environment and the healthcare industry is no different.

While digital transformation in life sciences has previously lagged, it is evident that recent events have worked as a catalyst for change. If companies want to stay competitive and meet the evolving needs and demands of patients and payers, there is strong evidence to support the need for restructuring business models and adapting to new technologies. So, why has there historically been such slow adoption of new technology?

Firstly, there is a lack of understanding around the range of technologies that are currently available and evolving, and it is now clear who within an organization should implement digital transformation. The second challenge is the lack of internal know-how and the need to recruit digital expertise or partner with an expert company. Lastly, many organizations hesitate to invest large amounts into an area where they lack a comprehensive understanding and therefore the ability to predict the return on their investment.

 

A Catalyst for Change

It is almost a cliché to say that COVID-19 has catalyzed life sciences and healthcare trends – but it’s true. The pandemic has caused a global health crisis that has changed the life sciences ecosystem. The healthcare industry has had to adopt new technologies to continue to develop their products and to also aid pharmaceutical companies in their mission to treat COVID-19. Key industry changes have affected regulatory compliance, potentially altering the future of clinical trials, and revolutionizing business and patient engagement models. But will these accelerated advances introduced during the COVID-19 crisis remain in the post-pandemic arena?

COVID-19 has significantly changed the face of the life sciences industry, both in the way it is perceived by the public and also in the way it operates

 

A Positive Impact on the Industry

There are many instances in which technology has shown a powerful and positive impact on the industry. Digital-first businesses, patient engagement models, and decentralized clinical trials are but a few. But what technology also enables is the ability to demonstrate greater resilience in planning, resourcing, and performance of activities – especially during product development and of course when re-thinking how to leverage data across different organizations. It is this, coupled with the opportunity to reduce time-to-market, which makes the digital transformation so effective.

Even before the emergence of COVID-19, virtual audits offered a way to reduce the time and expense of site-based audits, whilst ensuring they challenges and checked all relevant systems and procedures.

As the pandemic has necessitated regional, national, and international lockdowns, onsite audits have become not just inconvenient or unsafe, but often impossible. Also, the urgent need for new COVID-19 treatments and vaccines has made careful quality assurance processes more important than ever.

Postponing audits simply was not an acceptable option, and rescheduling audits created a risk of backlogs that could put further strain on resources and create unacceptable delays when site-based visits were reintroduced. The industry has had to think outside the box and consider options perhaps previously discounted. There are many tools available to facilitate comprehensive facility tours. These include:

Google Maps – to provide a street view of the site.

Drones – to provide options for viewing around and inside the facility.

Live streaming via mobile technologies such as a 360-degree camera – to enable more detailed views.

In-site cameras – to give auditors the ability to review video or recordings from the operations floor.

Photographs and facility blueprints – to offer additional facility details.

Emerging technology – to combine approaches for an even more realistic experience. Consider 3D mapping or augmented reality (AR) that overlays CAD drawings onto a video that is recorded using a mobile 360-degree camera, or a virtual reality (VR) demonstration of activities that simulates real-world scenarios in a safe, remote environment.

 

Looking to the Future

We should be asking – what have we learned, and will we maintain the momentum that the pandemic has created? COVID-19 has significantly changed the face of the life sciences industry, both in the way it is perceived by the public and also in the way it operates.

However, there remain several unknowns that could affect the future of the pharmaceutical and R&D industries. Will the unprecedented level of cross-industry cooperation and partnership that we are seeing today foster a new collaborative innovation model? We’d like to think so, but should it have taken a global pandemic to realize the potential benefits and how can we ensure we leverage the opportunities this has given us in the future?

The pandemic may also accelerate the entry of new players into the market, as they invest in health monitoring devices and platforms for virtual engagement. We have learned of discussions around COVID passports to enable safe international travel, witnessed an increased demand for home blood-oxygen monitors, and seen a new vigor for maintaining a healthy lifestyle with the desire to keep track using your mobile device. The pandemic has certainly struck a chord, and not just with how we develop and maintain products. It has also driven a greater demand from the patient population. We can be reassured that technology will play a significant role well beyond the COVID-19 ‘normality.’ Our lifestyles have changed significantly, with an increasing reliance on having information available on-demand. We can get the latest information on infection rates, hospitalizations, deaths, and vaccinations via tracking apps on our smartphones; health appointments are routinely done using video conferencing; we have access to at-home, rapid testing that provides immediate results and could facilitate the opening of entertainment venues, greater flexibility for hospitality, and the freedom to enjoy international travel once more. But will this represent the new normal? For the industry to keep up with patients’ expectations, some of these changes will need to continue and even develop further to ensure the availability of safe products for patients when they need them. With discussions having started at the governmental/country level on how to design tomorrow’s critical healthcare infrastructure supported by cutting-edge, enabling technologies, we can, at last, be confident that the healthcare industry is acknowledging the importance of digital transformation.

To remain competitive, to develop and maintain their products, and to ensure a healthy patient population, businesses, and leaders will have to step aboard.

Related posts
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Points de vigilance vis-à-vis de la communication institutionnelle en France
Points de vigilance vis-à-vis de la communication institutionnelle en France
23rd November 2021
Search
Upcoming Webinars

May 10th, 2022

Using Real World Evidence to Transform Drug Development and Evaluation: Opportunities and Challenges

04:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
4 May

Francesco Lanucara’s latest article discusses how important it is to provide clear information and keep up with regulatory guidelines.

Read the article here: https://lnkd.in/dFt4KBVy

For this and more articles subscribe to our newsletter.
#cellandgene #lifescience #cmc #ilap

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • What was especially important to me was their ability to get a team, with the right experience, together so quickly.

    Mid-size Biotech
    Head of Outsourcing
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for